

Daring to Go Beyond

CELLTRION EARNINGS RELEASE

THIRD-QUARTER 2026

2026.10.27

Disclaimer

The financial information contained in this document is consolidated earnings results based on K-IFRS.

This document is provided for the convenience of investors only before the external review is completed. The results of the external auditor's review may cause some changes in this document.

This document contains 'forward-looking statements' related to the business performance, market condition, future events and plan. Therefore, the recipients of this document shall be aware that the forward-looking statements set forth herein may not correspond to the actual business performance of the company due to changes in the business/industry environment and the long-term business plan of the company.

The purpose of this document is not to recommend investment in the company. The company hereby expressly disclaims any and all liability resulting from investors' reliance on the information contained herein.



01

3Q26 Financial Highlights

3Q26 Financial Highlights

Record-High Quarterly Sales and Operating Profit, with OP Surpassing KRW 500 bn
 Driven by accelerating growth of Young Products and solid prescription of Advanced Products

[Unit: KRW billion]

	3Q26	2Q26	QoQ	3Q25	YoY
Sales	1,575.5	1,393.7	+13.0%	1,029.0	+53.1%
Biologics	1,359.9	1,263.9	+7.6%	961.3	+41.5%
Non-Biologics	215.6	129.8	+66.1%	67.7	+218.5%
Operating Profit	525.3	451.8	+16.3%	301.4	+74.3%
OP Margin	33.3%	32.4%	+0.9%p	29.3%	+4.0%p

Sales Increased +53.1% YoY

- Young Products grew more than 70% YoY, while Advanced Products also delivered growth, contributing **the record-high sales**
- The 5 products launched in 2025 generated KRW 388.0bn in 3Q sales. 9M26 revenue exceeded KRW 900bn, over 2.5x the FY2025 level.
- Non-Biologics revenue grew 219% YoY, driven by higher CMO revenue from Eli Lilly. CMO to remain a key growth driver going forward.

OP Increased +74.3% YoY

- Improved product mix, driven by high-margin new products, led to operating profit growth outpacing revenue growth by 21.2%p, resulting in record-high quarterly operating profit. [Young Products Revenue Share: 42%(3Q24) → 54%(3Q25) → 67%(3Q26)]
- OP margin reached 33.3%, up +4.0%p from 29.3% 3Q25 **on a richer product mix and fixed-cost leverage**
 - OPM Trend: 23.6%(3Q24) → 29.3%(3Q25) → 33.3%(3Q26)


→ Sales growth and margin improvement are expected to continue into 4Q, supported by sustained high growth of Young Products and geographic expansion

Biologics Global Market Sales




- **Young Products:** Sales grew +74% YoY to over **KRW 900 bn**, with their share of Young Products revenue expanding to **67%**
 - Revenue share of the Young products is projected to reach the 70%+ in 4Q, driven by geographic expansion including US launches of Omlyclo and Eydenzelt
- **Advanced Products:** Sales grew +3% YoY on steady demand in key markets, **maintaining profitability** through selective sales strategies

Quarterly Comparison



Annual Forecast



* Advanced: Remsima, Truxima, Herzuma / Young: RemsimaSC, Yuflyma, Vegzelma, Zymfentra, Steqeyma, Stoboclo & Osenvelt, Avtozma, Omlyclo, Eydenzelt

* 2023: Pre-merger Celltrion Healthcare's sales

Biologics Sales (by Product)





- **High-margin Young Products increased KRW 384.7 bn YoY driving company-wide growth. Sales of the 5 new Products stayed above 4x YoY for a second consecutive quarter**
 - Remsima SC/Zymfentra grew on rising Europe market share and higher U.S. prescriptions (approx. 2x YoY). Yuflyma held its No.1 position in Europe, and sales kept expanding on the strategic U.S. pricing policy
- **Advanced Products** grew YoY, serving as a stable earnings base led by Remsima’s high market share and Truxima’s U.S. No.1 rank in M/S

High-margin Young Products ▲ KRW 384.7 bn

Advanced Products* ▲ KRW 13.9 bn

[Unit: KRW billion]



* 5 new products: Steqeyma, Stoboclo & Osenvelt, Avtozma, Omlyclo, Eydenzelt
* Advanced Products: Launched before 2020 / Young Products: Launched between 2020–2024 / 5 new products: Launched in 2025 and thereafter

Five New Products Positioned for Accelerated Growth




- Combined with the first-mover advantage of advanced products and differentiation of young products, **larger market opportunities, direct sales capabilities, and portfolio synergies** strengthened the business environment for the five products launched in 2025.
- With expanded market opportunities and stronger commercial capabilities, **the five newly launched products are expected to achieve higher average revenue per product in their fifth year post-launch than existing products.**

—○— **Advanced** Remsima/Inflectra · Truxima · Herzuma

—○— **Young** Remsima SC · Yuflyma · Vegzelma


—●— **5 New Products** Omlyclo and 4 others

Product Competitiveness & Market Potential



* Evaluated across 5 metrics (Market size, Number of competitors, First-mover status, Product differentiation, and Sales model(if it's Direct sales)) on a 3-point scale per product group.

Revenue per Product by Launch Year



* Average revenue per product, setting launch year as Year 1 (Y1). Advanced and Young products reflect actual results, while the 5 New Products (dotted line) are company estimates.

* Estimates for the 5 New Products: Based on Y3–Y5 growth rates of Advanced products, incorporating product-group competitiveness and market opportunity factors.

- Net debt rose slightly amid a drop in cashable assets, but debt ratio remains stable in low 30%, below the domestic major corporate average

Statement of Financial Position Summary


[Unit: KRW billion]

Category	End of 2025	3Q26
Total Assets	22,335	22,915
Current Assets	6,205	6,666
- Cashable Assets ¹	1,237	1,155
- Trade Receivables	1,790	2,291
- Inventory Assets	2,804	2,695
Non-current Assets	16,130	16,249
- Intangible Assets	13,778	13,689
Total Liabilities	4,982	5,447
Current Liabilities	4,454	4,898
Non-current Liabilities	529	549
* Borrowings (Long- and Short-term)	3,690	3,755
Shareholder's Equity	17,353	17,468
Issued Capital	239	251
Share Premium	14,190	14,247
Retained Earnings	4,407	3,267
Accumulated other comprehensive income	310	57.3
Other components of equity	(1,938)	(503)

1. Cashable Assets: cash and cash equivalent, and short-term financial instrument

Net Debt and Debt-Equity Ratio

[Unit: KRW billion]



1. Net debt: borrowings (long & short term) – cashable assets

2. Debt to Equity Ratio: total liabilities / shareholder's equity

3. Average debt ratio of large conglomerates (manufacturing sector) based on the Bank of Korea's "Corporate Management Analysis."



02


Global Commercial Update

Remsima SC & Zymfentra (Infliximab SC)




- **Remsima SC** achieved 34% market share in 2Q26, **breaking quarterly high** driven by steady European prescription growth
- **Zymfentra** sustains **quarterly prescription growth**, with further gains expected from higher-dose and RA trials and expanded PBM coverage

Remsima SC Prescription Trend in Europe



Zymfentra Prescription Trend in the US



1. Based on EU5 infliximab market


* Data based on SC dose-adjusted prescription volume * Source: IQVIA, Farminform

* Source: Symphony Health


Yuflyma (Adalimumab) & Vegzelma (Bevacizumab)



- **Yuflyma** solidified No. 1 position in Europe with continued share gains; **accelerating US market penetration** via strategic pricing
- **Vegzelma** sustained 30%+ market share and No.1 in Europe; **expanding global sales** following formulary listings with 2 major US PBMs (2026 Jul)
 - Secured No. 1 market share in key Asian countries leveraging direct sales (2Q26: Japan 63%, Malaysia 25%)



* Market share based on prescription volume
* Source: IQVIA, Farminform, Symphony Health




* Market share based on prescription volume
* Source: IQVIA, Farminform, Symphony Health

Global Sales Trend of Five New Products



- 3Q combined revenue of 5 New Products surged by +335% YoY to KRW 388bn, driven by balanced portfolio growth
- Growth was particularly driven by rapid prescription expansion of **Omlyclo** (first-mover advantage without competition), **Avtozma** (consecutive tender wins in Europe), and **Stoboclo/Osenvelt** (listed on preferred formularies of 3 out of the top 5 PBMs)
- Continued ramp-up and expansion into new markets and indications are expected to drive **strong growth through 4Q26 and 2027**.



Major Market Launch & Early Commercial Results		
 ustekinumab	Europe '24.11	- Sales accelerated post-auto-injector formulation launch (2Q26) - Prescription growth expected from UC indication expansion
	US '25.03	- Full-label approved; formulary coverage expanded from 1 to 2 of the top 3 PBMs - Reached 13% M/S in Year 1 (26.3Q)
 omalizumab	Europe '25.09	- Established a dominant position in Europe as a first-mover without competitors - Achieved 30% M/S within one year of launch (26.2Q)
	US '26.10	- Launched as sole first-mover, Immediate major PBM preferred listing & signed deal with a major distributor - Exclusive deal with a major healthcare firm & listed as preferred (original excluded)
 denosumab	Europe '25.12	Accelerating expansion via acquired Gifrer sales network
	US '25.07	Access to 3 of the top 5 PBMs, securing a competitive prescription advantage
 tocilizumab	Europe '26.01	- Secured 80% French private hospital M/S - Won Norway & Dutch tenders
	US '25.10	- Listed as a preferred on commercial formularies of top 3 PBMs - Exclusive deal with a major healthcare firm & listed as preferred (original excluded)
 afibercept	Europe '26.01	UK NHS & Portugal public tender wins support broader supply rollout; paving the way for M/S expansion set for 2027
	US 2H26(e)	2H launch prep progressing on track

Accelerating growth through EU market penetration and U.S. launch, leveraging a first-mover advantage with no competition.

- Europe: **Reached 30% M/S within one year of launch**, driven by differentiated competitiveness as the sole Xolair® biosimilar
- US: Since its Oct. 2026 launch, secured exclusive supply over the originator, preferred PBM listing, and major distribution deals
→ **Broader insurance, hospital, and pharmacy access to drive prescription growth**

Product Overview



- ✓ Molecule: Omalizumab
- ✓ Main Indications: Allergic Asthma, Chronic Spontaneous Urticaria(CSU), Food Allergy, etc.
- ✓ Market Size*
 - Approx. KRW 8.3T (\$5.9B in 2025)
 - Expanding market size driven by indication additions such as food allergies (CAGR 16% ['21-'25])

Product Competitiveness


	Original	Omlyclo
Shelf Life	18 months	24 months
Room Temp. Storage	48 hours	Up to 7 days
Re-refrigeration	X	O
LATEX	Contains	Latex-free

- ✓ Diverse Dose & Device: Broadening options with various doses (75/150/300mg) and Auto-Injectors (AI)

* Source: IQVIA, (KRW market size calculated at USD/KRW = 1,400)

Quarterly Revenue Growth Trend

[Unit: KRW billion]



* Market share based on prescription volume


* Source: IQVIA, Farminform

Advanced Products (Remsima IV, Truxima, Herzuma) (Infliximab IV, Rituximab, Trastuzumab)



- Advanced Products secure sustainable revenue foundation, **maintaining a firm global position built over time**
 - Remsima/Inflectra:** Strengthening infliximab leadership with a full formulation lineup spanning Lyophilized, Liquid, and SC
 - Truxima:** Solidifying No.1 position (2Q26 M/S: 38%) driven by long-term US supply contracts
 - Herzuma:** Enhancing market dominance by reaching 80%+ market share in Japan


Remsima/Inflectra Global M/S



* Based on infliximab IV market (Excluding SC)

* Source: IQVIA, Farminform, Symphony Health

Truxima Global M/S



* Market share based on prescription volume

* Source : IQVIA, Farminform, Symphony Health


03

Development & Production Strategy

Mid-to-Long-Term Pipeline Roadmap

Expanding Biosimilar Portfolio to 41 Products by 2038


Biosimilar



Developing 25 New Drug Candidates



Antibody-based (ADC/Bispecific Antibodies)



Obesity/FcRn



Biosimilar R&D Update & Mid/Long-Term Strategy





- Submitted an application for regulatory approval for the Cosentyx® biosimilar and Keytruda® biosimilar in the US and Korea respectively
- IND¹ amendment approved for the Darzalex® biosimilar Phase 3 trial in Europe (patient count reduced: 486→394), **lowering R&D costs**
- 7 biosimilar pipelines progressing on track; expanding portfolio to 18 products by 2030 and 41 by 2038 to reinforce global leadership**

R&D Progress

Indication	Product Name	Global Market Size (2025)	Development Status	
			US	EU
Autoimmune Diseases	CT-P53 (OCREVUS® Biosimilar)	\$9.0bn	In Phase 3 Clinical Trial	
	CT-P55 (COSENTYX® Biosimilar)	\$11.2bn	Regulatory filing submitted	Regulatory filing submitted
	CT-P52 (TALTZ® Biosimilar)	\$7.0bn	In Phase 1 Clinical Trial	
	CT-P45 (ENTYVIO® Biosimilar)	\$7.3bn	In Phase 1 Clinical Trial	
	CT-P68 (TREMFA® Biosimilar)	\$10.5bn	In Phase 1 Clinical Trial (IND ¹ Approved by MFDS)	
Oncology	CT-P6 SC (HERCEPTIN SC® Biosimilar)	\$1.2bn ²	-	Regulatory filing submitted
NSCLC ³	CT-P51 (KEYTRUDA® Biosimilar)	\$36.5bn	In Phase 3 Clinical Trial (Regulatory filing submitted for Korea)	
Multiple Myeloma	CT-P44 (DARZALEX® Biosimilar)	\$14.4bn	In Phase 3 Clinical Trial	

Portfolio Status

----- Pre-approval



1. IND (Investigational New Drug Application): A regulatory submission to obtain approval from relevant authorities to commence clinical trials in humans
2. Based on the Trastuzumab market in Europe (2025) 3. NSCLC: Non-Small Cell Lung Cancer * Source: IQVIA, J&J(DARZALEX)

Diversification of New Drug Pipeline Modalities

- Expanding beyond ADCs and multispecific antibodies into obesity and FcRn therapies, **diversifying modalities and therapeutic areas to drive long-term growth**

CT-G32 Next-Gen Obesity Drug Targeting Four Receptors

1 Demonstrated superior efficacy vs. comparator

- Superior weight loss and lean body mass (LBM) preservation vs. a triple-target comparator at equal doses, targeting first-in-class status

2 Building a Next-Generation Obesity Portfolio

- Advancing parallel development of oral and long-acting obesity therapies

3 Indication Expansion to Metabolic Diseases

- Expanding indications into sarcopenia, diabetes, and other metabolic diseases to enhance lifecycle management

CT-P77, Next-Gen FcRn Inhibitor Based on Differentiated Safety Profile

1 Differentiated FcRn-targeting fusion protein on track

- Developing a best-in-class therapy with high-concentration SC formulation and differentiated properties for greater patient convenience

2 IND submission & preclinical data presentation planned by year-end

- Preclinical data presentation planned at Antibody Engineering & Therapeutics (AET) in San Diego, December 2026
- IND submission planned by year-end, based on preclinical results

CT-G32: Late 2026, Preclinical Results Release

CT-G32: 1Q27, IND Filing

Oral Obesity Treatment: 2H28, IND Filing

CT-P77: Late 2026, Preclinical Results Release & IND Filing



2026



2027



2028



04

Appendix

Earnings Summary Consolidated



Quarterly

	3Q25	4Q25	1Q26	2Q26	3Q26
Sales	1,029	1,330	1,145	1,394	1,576
Cost of Sales	403	477	459	530	621
Gross Profit	626	854	686	864	955
GP Margin	60.8%	64.2%	59.9%	62.0%	60.6%
SG&A	325	379	364	412	430
- R&D Expenses	55	53	62	64	71
Operating Profit	301	475	322	452	525
OP Margin	29.3%	35.7%	28.1%	32.4%	33.3%
Profit before Income Tax	378	528	432	458	103
Net Profit	332	528	350	371	78
NP Margin	32.3%	39.7%	30.6%	26.6%	5.0%

* Figures are rounded to the nearest KRW 1 billion; minor discrepancies may occur due to rounding

9-Month Cumulative

[Unit: KRW billion]

	2025	2026	YoY
	2,832	4,114	+45.3%
	1,219	1,609	+32.0%
	1,613	2,505	+55.3%
	57.0%	60.9%	+3.9%p
	920	1,206	+31.1%
	158	197	+24.8%
	693	1,299	+87.4%
	24.5%	31.6%	+7.1%p
	626	993	+58.7%
	504	800	+58.8%
	17.8%	19.4%	+1.6%p

Sales Mix by Product

Quarterly

	3Q25	4Q25	1Q26	2Q26	3Q26
Sales	1,029	1,330	1,145	1,394	1,576
Biologics	961	1,252	974	1,264	1,360
Advanced Products	440	518	393	439	454
Remsima IV	265	285	214	253	268
Truxima	126	169	137	152	140
Herzuma	49	64	43	34	47
Young Products	521	735	581	825	906
Remsima SC	185	236	157	200	219
Yuflyma	144	104	114	195	183
Vegzelma	75	155	46	69	80
Zymfentra	28	58	53	47	36
Steqeyma	35	42	40	50	49
Omlyclo	28	49	72	117	132
Eydenzelt	2	6	7	10	14
Stoboclo/Osenvelt	20	71	69	74	112
Avtozma	4	14	25	64	81
Non-Biologics	68	78	171	130	216
CT Pharm/Chemical	63	70	69	73	73
CMO	-	-	96	50	129
Others	5	8	5	7	14

9-Month Cumulative

[Unit: KRW billion]

	2025	2026	YoY
Sales	2,832	4,114	+45.3%
Biologics	2,612	3,598	+37.8%
Advanced Products	1,275	1,286	+0.8%
Remsima IV	764	734	-3.9%
Truxima	358	429	+19.9%
Herzuma	154	123	-19.9%
Young Products	1,336	2,312	+73.0%
Remsima SC	482	575	+19.5%
Yuflyma	399	493	+23.6%
Vegzelma	214	195	-8.8%
Zymfentra	64	135	+110.8%
Steqeyma	92	138	+50.7%
Omlyclo	50	321	+542.3%
Eydenzelt	3	31	+839.4%
Stoboclo/Osenvelt	28	254	+814.4%
Avtozma	5	170	+3101.9%
Non-Biologics	221	516	+133.9%
CT Pharm/Chemical	204	215	+5.8%
CMO	-	275	-
Others	17	26	+51.7%

* Figures are rounded to the nearest KRW 1billion; minor discrepancies may occur due to rounding

Advanced Therapeutics within Everyone's Reach

Thank you